<DOC>
	<DOCNO>NCT01312311</DOCNO>
	<brief_summary>The investigator evaluate weekly docetaxel plus 3-weekly cisplatin regimen first-line therapy recurrent metastatic nasophayngeal cancer</brief_summary>
	<brief_title>Weekly Docetaxel Plus Cisplatin First-line Therapy Nasopharyngeal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>histologically confirm nasopharyngeal cancer chemotherapy radiotherapy naive ( , include patient complete 6 month enrollment ) ECOG 01 least one measurable lesion cancer pregnat docetaxel hypersentitivity history severe heart pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>nasopharyngeal cancer</keyword>
	<keyword>weekly docetaxel</keyword>
	<keyword>cisplatin</keyword>
</DOC>